drugset

drugset / Trial / NCT05472610

Study of Efficacy of BZ019 in Large B-cell Lymphoma

NCT05472610 ↗

Phase 2 Unknown 36 enrolled Shanghai Mengchao Cancer Hospital Shanghai Cell Therapy Group Co.,Ltd · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single arm,open-label, non-randomized phase 2 study to determine the efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.

Timeline

Start: 2021-06-04
Primary completion: 2023-01
Completion: 2023-01

Publications

Zhang Y, Lin Z, Zhang F, Chen X, Yang Y, Fu X, Li Z, Sun Y, Qian Q. Rapid response in relapsed follicular lymphoma with massive chylous ascites to anti-CD19 CAR T therapy using Piggy Bac: A case report. Front Immunol. 2022 Dec 1;13:1007210. doi: 10.3389/fimmu.2022.1007210. eCollection 2022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BZ019	Cell therapy	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Fludarabine	Small molecule	—	—

Indications